Genelux Corp Sustainability Reports
Genelux Corporation is a clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies. The company is primarily focused on designing targeted cancer therapeutics to treat aggressive and difficult-to-manage solid tumor types.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG0044BNBY5
1 reports from 2023 to 2023
Company Profile
Genelux Corporation is a clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies. The company is primarily focused on designing targeted cancer therapeutics to treat aggressive and difficult-to-manage solid tumor types.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
